Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities

被引：30

作者：

Ramamoorthi, Ganesan ^{[1
]}

Kodumudi, Krithika ^{[1
]}

Gallen, Corey ^{[1
]}

Zachariah, Nadia Nocera ^{[1
,2
]}

Basu, Amrita ^{[1
]}

Albert, Gabriella ^{[1
]}

Beyer, Amber ^{[1
]}

Snyder, Colin ^{[1
]}

Wiener, Doris ^{[1
]}

Costa, Ricardo L. B. ^{[1
,2
]}

Czerniecki, Brian J. ^{[1
,2
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Clin Sci & Immunol Program, Tampa, FL USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Breast Oncol, Tampa, FL USA

来源：

SEMINARS IN CANCER BIOLOGY | 2022年 / 78卷

关键词：

Breast cancer; Disseminated cancer cells; Metastasis; Th1 immune cells and immunotherapy; DISSEMINATED TUMOR-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; MICROENVIRONMENTAL REGULATION; METASTATIC OUTGROWTH; ADJUVANT THERAPY; IMMUNE-SYSTEM; BONE-MARROW; TAMOXIFEN; HER2; IMMUNOTHERAPY;

D O I：

10.1016/j.semcancer.2021.02.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic spread in breast cancer patients is the major driver of cancer-related deaths. A unique subset of cells disseminated from pre-invasive or primary tumor lesions are recognized as the main seeds for metastatic outgrowth. Disseminated cancer cells (DCCs) can migrate to distant organs and settle in a dormant state for a prolonged period until they emerge to overt metastases. Understanding the biology of breast cancer cells dissemination, dormancy and reactivation to form overt metastases has become an important focus. In this review, we discuss the recent advancements of molecular pathways involving breast cancer cell dissemination, role of chemokine-chemokine receptor networks in DCCs migration, DCCs phenotypic heterogeneity and unique genes signatures in tumor dormancy, microenvironmental regulation and specific niches that favors DCCs homing and dormancy. In addition, we also discuss recent findings relating to the role of immune response on DCC dissemination and dormancy. With recent advances in the field of immunotherapy/targeted therapy and its beneficial effects in cancer treatment, this review will focus on their impact on DCCs, reversal of stemness, tumor dormancy and metastatic relapse.

引用

页码：78 / 89

页数：12

共 153 条

[1]

Abolmaaty A, 1997, MICROBIOS, V91, P37

[2] Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer [J].

Abubakar, Mustapha ;

Figueroa, Jonine ;

Ali, H. Raza ;

Blows, Fiona ;

Lissowska, Jolanta ;

Caldas, Carlos ;

Easton, Douglas F. ;

Sherman, Mark E. ;

Garcia-Closas, Montserrat ;

Dowsett, Mitch ;

Pharoah, Paul D. .

MODERN PATHOLOGY, 2019, 32 (09) :1244-1256

[3] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics [J].

Akinleye, Akintunde ;

Rasool, Zoaib .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)

[4] Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients [J].

Aktas, Bahriye ;

Tewes, Mitra ;

Fehm, Tanja ;

Hauch, Siegfried ;

Kimmig, Rainer ;

Kasimir-Bauer, Sabine .

BREAST CANCER RESEARCH, 2009, 11 (04)

[5] EMT: 2016 [J].

Angela Nieto, M. ;

Huang, Ruby Yun-Ju ;

Jackson, Rebecca A. ;

Thiery, Jean Paul .

CELL, 2016, 166 (01) :21-45

[6] IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression [J].

Aqbi, Hussein F. ;

Wallace, Matthew ;

Sappal, Samay ;

Payne, Kyle K. ;

Manjili, Masoud H. .

JOURNAL OF LEUKOCYTE BIOLOGY, 2018, 103 (06) :1219-1223

[7] Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton [J].

Barkan, Dalit ;

Kleinman, Hynda ;

Simmons, Justin L. ;

Asmussen, Holly ;

Kamaraju, Anil K. ;

Hoenorhoff, Mark J. ;

Liu, Zi-yao ;

Costes, Sylvain V. ;

Cho, Edward H. ;

Lockett, Stephen ;

Khanna, Chand ;

Chambers, Ann F. ;

Green, Jeffrey E. .

CANCER RESEARCH, 2008, 68 (15) :6241-6250

[8] Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor [J].

Barok, Mark ;

Balazs, Margit ;

Nagy, Peter ;

Rakosy, Zsuzsa ;

Treszl, Andrea ;

Toth, Eniko ;

Juhasz, Istvan ;

Park, John W. ;

Isola, Jorma ;

Vereb, Gyoergy ;

Szollosi, Janos .

CANCER LETTERS, 2008, 260 (1-2) :198-208

[9] Immunotherapy in breast cancer: Current status and future directions [J].

Basu, Amrita ;

Ramamoorthi, Ganesan ;

Jia, Yongsheng ;

Faughn, Jon ;

Wiener, Doris ;

Awshah, Sabrina ;

Kodumudi, Krithika ;

Czerniecki, Brian J. .

IMMUNOTHERAPY OF CANCER, 2019, 143 :295-349

[10] The immune system and response to HER2-targeted treatment in breast cancer [J].

Bianchini, Giampaolo ;

Gianni, Luca .

LANCET ONCOLOGY, 2014, 15 (02) :E58-E68

← 1 2 3 4 5 6 7 8 9 10 →